Board Unanimously Recommends Shareholders Accept Servier's $21.50 All-Cash Tender Offer

summarizeSummary

Day One Biopharmaceuticals' Board unanimously recommends shareholders accept Servier's all-cash tender offer of $21.50 per share, representing a substantial premium and providing immediate liquidity.

check_boxKey Events

• Board Recommends Tender Offer

  Day One's Board of Directors unanimously recommends that shareholders accept the tender offer and tender their shares to Servier Detroit Inc. at $21.50 per share.

• All-Cash Acquisition Launched

  Servier Detroit Inc., a subsidiary of Servier S.A.S., has officially launched a tender offer to acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share in cash.

• Significant Premium Offered

  The $21.50 per share offer price represents a 114% premium to Day One's closing price on March 3, 2026 (unaffected date) and a 68% premium to the closing price on March 5, 2026 (day prior to announcement).

• Equity Awards to Accelerate

  All unvested stock options and restricted stock units will fully vest immediately prior to the effective time of the merger and be converted into cash payments.

auto_awesomeAnalysis

This SC 14D9 filing confirms and details the definitive agreement for Servier to acquire Day One Biopharmaceuticals for $21.50 per share in an all-cash tender offer. The Board's unanimous recommendation, supported by a fairness opinion from Centerview Partners, highlights the significant premium offered to shareholders (114% to the unaffected price). The comprehensive negotiation process, involving multiple potential acquirers, suggests the Board diligently pursued the highest value for shareholders. The deal provides immediate and certain liquidity, removing future operational and market risks for Day One shareholders. The acceleration of all unvested equity awards for executives and directors further aligns their interests with the transaction's success.